(Pharmaceutical Meta-Analytical Screening)
It is known that even twins have different microbiome(intestinal microbiome) environments. For this reason, it is difficult to develop an excellent microbiome solution without an accurate understanding of an individual's microbiome. HEM Pharma has secured excellent technology to find an accurate solution by creating an individual or disease-based cloned microbiome through independent patented technology PMAS(Pharmaceutical Meta-Analytical Screening) analysis in order to maximize the efficacy of the microbiome control solution. PMAS analysis is a meta-screening technology that selects microbiome solutions optimized for individuals by culturing the cloned microbiome in a system made similar to the intestinal environment, processing various probiotics, pharmabiotics(LBP), etc. based on individual fecal samples.
*Patent KR.10-2124474 / KR.10-2227382 / US.11237172.B2
Method for screening personalized intestinal environment-improving material and composition therefor
Homogenize the fecal sample by mixing it with PMAS culture medium
Divide the sample in the same amount (replication of intestinal microbes in the feces)
Treat the candidate substance to the divided samples
Incubate for a certain period of time in an anaerobic environment
Analyze the results of each well after culture
It establishes a purpose-oriented microbiome replication system based on a 96-well plate in order to enable high-speed screening(HTA), allowing technology to be utilized in various channels more quickly. Since it is possible to make 96 clones of microbiome on one plate by using feces from one person, and it is possible to simultaneously process various probiotics or pharmabiotics(LBP) can be simultaneously processed, probiotics or pharmabiotics customized for each individual’s different microbiome characteristics.